Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the company’s board of directors granted 12 new employees options to purchase an aggregate of 39,000 shares of the company’s common stock with a per share exercise price of $19.44, the closing trading price on the grant date, and 19,500 restricted stock units.  The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company. (Original Source)

Shares of Relypsa are up nearly 2% to $19.09 in after-hours trading. RLYP has a 1-year high of $42.26 and a 1-year low of $10.26. The stock’s 50-day moving average is $25.64 and its 200-day moving average is $24.20.

On the ratings front, Relypsa has been the subject of a number of recent research reports. In a report issued on January 4, BTIG analyst Tim Chiang initiated coverage with a Buy rating on RLYP and a price target of $45, which represents a potential upside of 141.3% from where the stock is currently trading. Separately, on December 28, Cantor Fitzgerald’s Mara Goldstein reiterated a Buy rating on the stock and has a price target of $42.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Tim Chiang and Mara Goldstein have a total average return of 4.4% and -10.7% respectively. Chiang has a success rate of 54.8% and is ranked #726 out of 3582 analysts, while Goldstein has a success rate of 28.8% and is ranked #3449.

Overall, one research analyst has rated the stock with a Sell rating, 9 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $47.50 which is 154.7% above where the stock opened today.

Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases